Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11572881 | 0.88 | ALDH1A1 (0.76) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL28109022 | 0.84 | MAPT (0.78) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL17847424 | 0.84 | CA12 (0.70) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL3555904 | 0.82 | WDR5 (0.64) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL23014399 | 0.81 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL23014074 | 0.81 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL94655 | 0.80 | LMNA (0.77) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL8752463 | 0.80 | CA12 (1.00) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL3369379 | 0.79 | KMT2A (0.78) | ALDH1A1KMT2AMEN1MAPTLMNA | |
| SCHEMBL8752540 | 0.79 | KMT2A (0.78) | ALDH1A1KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | claimed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | claimed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | claimed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | GLUCOX BIOTECH AB (SE) | 2019-02-05 | — | — | US | disclosed |
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2018-09-27 | — | — | US | disclosed |
| EP-3233072-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | Glucox Biotech AB (SE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096720-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | GLUCOX BIOTECH AB (SE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271810-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NADPH OXIDASE | CYBB, NOX4, NOX1 | ALDH1A1 195/4885KMT2A 3543/4885MEN1 3350/4885 |
| US-10195167-B2 | Compounds for use in the treatment of conditions associated with NADPH oxidase | CYBB, NOX4, NOX1 | ALDH1A1 195/4885KMT2A 3543/4885MEN1 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.